CONCERT PLUS: An Open-Label Extension of the CONCERT Protocol (DIM18) Evaluating Dimebon (Latrepirdine) in Patients with Alzheimer's Disease [EXTENSION OF 700041072]

Trial Profile

CONCERT PLUS: An Open-Label Extension of the CONCERT Protocol (DIM18) Evaluating Dimebon (Latrepirdine) in Patients with Alzheimer's Disease [EXTENSION OF 700041072]

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs Latrepirdine (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms CONCERT-PLUS
  • Sponsors Medivation
  • Most Recent Events

    • 06 Mar 2013 Planned number of patients changed to 850.
    • 06 Mar 2013 Status changed from completed to discontinued.
    • 06 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top